---
title: "A therapy that aims to reset the body's clock reaches its first human test"
description: "A US biotech company has dosed the first patient in a trial of ER-100, a treatment that tries to reverse cellular ageing by partly reprogramming cells. The early study targets blinding eye disease, and scientists caution that promise in animals is no guarantee in people."
category: "Science"
category_url: https://newsparlor.com/category/science
author: "Liam Fitzgerald"
published: 2026-07-16T04:29:00.000Z
updated: 2026-07-16T04:29:00.000Z
canonical: https://newsparlor.com/article/gene-therapy-aging-human-trial-er100
tags: ["gene-therapy", "ageing", "epigenetics", "clinical-trials", "longevity"]
---
# A therapy that aims to reset the body's clock reaches its first human test

A US biotech company has dosed the first patient in a trial of ER-100, a treatment that tries to reverse cellular ageing by partly reprogramming cells. The early study targets blinding eye disease, and scientists caution that promise in animals is no guarantee in people.

For years the idea of turning back the biological clock has belonged more to the laboratory and the longevity conference than to the clinic. That has now shifted a little. A Boston-based company, Life Biosciences, says it has given the first human patient a treatment designed not merely to slow ageing but to partly reverse it in a specific tissue.

The experimental therapy, called ER-100, was administered in what the company describes as the first clinical trial of partial epigenetic reprogramming in people. The [US Food and Drug Administration cleared the study earlier this year](https://www.medicaldaily.com/first-human-trial-reverse-aging-just-got-fda-clearance-what-epigenetic-reprogramming-actually-476076), and the [first patient was dosed in June](https://www.washingtontimes.com/news/2026/jun/16/first-human-dosed-cellular-reprogramming-drug-longevity-trial/). The firm's chairman is David Sinclair, the Harvard geneticist whose laboratory has long championed the theory behind the approach.

## What "reprogramming" means

Ageing is not only the ticking of years. At the level of the cell, it involves changes in which genes are switched on and off, a layer of control known as the epigenome that sits on top of the DNA sequence itself. Unlike mutations to the DNA, these settings can in principle be reset.

ER-100 tries to do exactly that. It uses three of the four so-called Yamanaka factors, the proteins discovered by the Nobel laureate Shinya Yamanaka that can wind a mature cell back towards a youthful, stem-cell-like state. Crucially, the therapy leaves out the fourth factor and aims for only a partial reset, the goal being to restore a cell's vigour without erasing its identity or its memory of what kind of cell it is.

## Starting with the eye

The trial does not attempt anything so sweeping as rejuvenating a whole body. It focuses on two serious eye conditions, open-angle glaucoma and a disorder called non-arteritic anterior ischemic optic neuropathy, in which the retinal cells that carry visual signals to the brain are damaged and vision is lost, often for good. If reprogramming can coax those cells back to health, it would offer something current treatments cannot.

The choice of the eye is deliberate. It is a contained, accessible part of the body where a therapy can be delivered directly and its effects observed, limiting the risk that reprogramming spreads where it is not wanted. The underlying idea rests on [earlier work in mice, published in 2020, that restored sight in ageing animals](https://www.nature.com/articles/d41586-026-01836-7) by resetting cells in this way.

## Reasons for caution

Scientists not involved in the work urge restraint. Reprogramming carries real risks: pushed too far, it can turn cells cancerous or strip them of their function, which is why the company stresses that its approach is partial and tightly controlled. The trial is a small, early-stage safety study, with initial results not expected until late this year or into 2027, and success in the eye would not by itself prove that ageing elsewhere in the body can be reversed.

There is debate, too, about how much of ageing this strategy can really address, and some researchers question whether the particular combination of factors is the best one. For now the field is watching closely. The experiment is less a breakthrough than a first real-world test of a bold theory, and its value will lie in what it reveals about whether the body's clock can be safely, and usefully, reset.